Transparency Market Research
Implantable Cardiac Monitor Market Predicted to Achieve 6.6% CAGR and Valued at USD 1.6 Billion by 2031- Report by Transparency Market Research, Inc.
March 18, 2024 10:30 ET | Transparency Market Research
Wilmington, Delaware, United States, March 18, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. -The implantable cardiac monitor industry was worth US$ 914.5 million in 2022. By the end of...
Emergen logo.png
Arrhythmia Monitoring Devices Market Size Worth USD 15.33 Billion in 2032 | Emergen Research
January 15, 2024 07:33 ET | Emergen Research
Vancouver, Jan. 15, 2024 (GLOBE NEWSWIRE) -- The global arrhythmia monitoring devices market size was USD 7.43 billion in 2022 and is expected to register a rapid revenue CAGR of 7.7% during the...
Global Atrial Fibrillation Market
Global $12.07 Bn Atrial Fibrillation Markets, 2017-2022, 2022-2027F, 2032F: Analysis, Forecasts and Competitive Landscape
October 26, 2023 04:18 ET | Research and Markets
Dublin, Oct. 26, 2023 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global atrial fibrillation market is...
Transparency Market Research
Anticoagulant Reversal Drugs Market Revenue to Cross USD 2.3 billion by 2031, Expanding at a CAGR of 11.3% - Exclusive Report by Transparency Market Research
October 17, 2023 03:40 ET | Transparency Market Research
Wilmington, Delaware, United States, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global anticoagulant reversal drugs market is projected to flourish at a CAGR of 11.3%...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces Research Published in The Journal of Clinical Investigation Reinforcing IC 100’s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues
September 22, 2023 06:35 ET | ZyVersa Therapeutics
Patients with chronic kidney disease (“CKD”) exhibit chronic systemic inflammation characterized by increased circulating levels of IL-1β, IL-6, and CRP.This study demonstrated that CKD-induced IL-1β...
AMR Logo.png
Clot Busting Drugs Market to Reach $60 Billion, Globally, by 2032 at 8.2% CAGR: Allied Market Research
July 24, 2023 09:55 ET | Allied Market Research
Portland,OR, July 24, 2023 (GLOBE NEWSWIRE) -- Allied Market Research has recently published a report, titled, “Clot Busting Drugs Market by Product (Thrombolytic Drugs, Anti-Platelet Drugs,...
Anthos Logo Transparent.png
Anthos Therapeutics Supported Global Survey of 3000+ Patients Prescribed Anticoagulants Detailing Impact of Patient-Relevant Bleeding (PRB) Presented at ISTH 2023
June 26, 2023 07:00 ET | Anthos Therapeutics
Patient-Centric Survey Conducted in Collaborationwith StopAfib.org and the National Blood Clot Alliance Findings Suggest “Patient-Relevant Bleeding” More Accurate Than Current Terminology,...
Anthos Logo Transparent.png
Regulatory Authorities in China and Japan Approve Clinical Trials for Anthos Therapeutics’ Dual-Acting Factor XI/XIa Inhibitor Abelacimab
June 08, 2023 11:10 ET | Anthos Therapeutics
Fewer than 26% of Chinese Patients with Atrial Fibrillation are Prescribed an Anticoagulant, while in Japan Almost One-Third of Patients are Undertreated Approximately 63% of Cancer Patients in China...
Anthos Logo Transparent.png
New Assessment Scale to Measure Adherence to Oral Anticoagulants Based on Impact of Patient Relevant Bleeding in Atrial Fibrillation Presented at ISPOR 2023
May 09, 2023 09:45 ET | Anthos Therapeutics
Anticoagulant Bleeding Burden Adherence Confidence Assessment Scale [ABBA-CAS] Created to Better Address an Important Treatment Gap in the Management of Atrial Fibrillation (AF) and Bring Patient...
Anthos Logo Transparent.png
New Assessment Scale to Capture Patient Relevant Bleeding to be Presented at ISPOR 2023
May 05, 2023 08:00 ET | Anthos Therapeutics
Additional presentation spotlights GARDENIA registry design in patientswith atrial fibrillation and atrial flutter Early Cost-Effectiveness Modeling for Patients with Atrial Fibrillation and Cancer...